
Supporting Information

One-Pot Method for Synthesis of 1-Aryl-2-Aminoalkanol Derivatives from the Corresponding Amides or Nitriles

Jan Otevrel,^{*,§} David Svestka,[§] Pavel Bobal^{*}

Department of Chemical Drugs, Faculty of Pharmacy
Masaryk University, Palackého 1946/1, 612 42 Brno, Czech Republic

*pbobal@icloud.com, *otevrel@icloud.com


§Both authors contributed equally to this work and appear here in alphabetical order

TABLE OF CONTENTS

1. Optimization of the Reaction Conditions	S2
2. Substrate Scope	S5
3. Determination of the Enantiomeric Purity of 8a , 8b , and 5a	S45
4. Identification of the Reaction Intermediates	S50
5. References	S61
6. HRMS and NMR Data	S62

1. Optimization of the Reaction Conditions

1.1 Optimization of the Hydride Loading and the Reaction Temperature



Optimization experiments were performed as follows: A solution of **1a** (0.3 g, 1.31 mmol) in an appropriate anhydrous solvent was treated with the corresponding hydride dropwise/portionwise at 0 °C (foaming). The resulting mixture was left to stir under the argon/air/oxygen-filled rubber balloon at ambient or slightly elevated temperature (55 °C) for 3–48 h (please, see **Tab. S1–S3** for further details). The initially formed deep-red color gradually disappeared during the reaction time, leaving the light-yellow colored solution.

TLC (SiO₂) CH₂Cl₂–MeOH (90:10) or CHCl₃–MeOH–NH₄OH (79:20:1).

Then the reaction mixture was carefully quenched by a dropwise addition of an aqueous solution of NaOH (5 M, 1 mL) at 0 °C and further diluted with an aqueous solution of NaOH (5 M, 15 mL). The organic and aqueous layers were separated and the aqueous phase was reextracted with toluene (5 × 15 mL). The combined organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated in vacuo.

The yellow oily residue was dissolved in 5 mL of Et₂O–MeOH, 5:1 and a solution of anhydrous oxalic acid (0.13 g, 1.1 equiv) in 5 mL of Et₂O–MeOH (5:1) was added dropwise. The resulting white precipitate was filtered off, washed several times with fresh Et₂O–MeOH (5:1), Et₂O, and dried in vacuo.

Table S1. Optimization of the hydride loading and the reaction temperature

entry	hydride	solvent	atm.	temp.	time	yield ^a	3a/4a ratio ^b	variable
1	SMEAH [70% in MePh, 5 equiv]	MePh [5 mL]	Ar	25 °C	48 h	30 mg	74:26	Hydride Load
2	SMEAH [70% in MePh, 10 equiv]	MePh [5 mL]	Ar	25 °C	48 h	60 mg	84:16	
3	SMEAH [70% in MePh, 15 equiv]	MePh [5 mL]	Ar	25 °C	48 h	145 mg	84:16	
4	SMEAH [70% in MePh, 20 equiv]	MePh [5 mL]	Ar	25 °C	48 h	162 mg	85:15	
5	SMEAH [70% in MePh, 10 equiv]	MePh [5 mL]	Ar	55 °C	24 h	79 mg	58:42	Temp.

Footnotes: Experiments were performed at the 1.3 mmol scale; SMEAH = sodium bis(2-methoxyethoxy)aluminum hydride; ^abased on the isolated yields, ^bmeasured by ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analyses of the isolated products (**Fig. S1**).

1.2 Alteration of the Hydride Type




Table S2. Alteration of the Hydride Type

entry	hydride	solvent	atm.	temp.	time	yield ^a	3a/4a ratio ^b	variable
6	DIBAH [25% in MePh, 30 equiv]	MePh [5 mL]	Ar	25 °C	48 h	252 mg	1:99	Hydride Type
7	LAH [7.5 equiv]	THF–MePh [1:1, 8 mL]	Ar	25 °C	48 h	74 mg	5:95	
8	LMAH [15 equiv]	THF–MePh [1:1, 8 mL]	Ar	25 °C	48 h	214 mg	48:52	

Footnotes: Experiments were performed at the 1.3 mmol scale; DIBAH = diisobutylaluminum hydride, LAH = lithium aluminum hydride, LMAH = lithium dimethoxyaluminum hydride; ^abased on the isolated yields, ^b measured by ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analyses of the isolated products (**Fig. S1**).

1.3 Optimization of the Solvent Type and the Reaction Atmosphere




Table S3. Optimization of the Solvent Type

entry	hydride	solvent	atm.	temp.	time	yield ^a	3a/4a ratio ^b	variable
9	SMEAH [70% in MePh, 15 equiv]	THF [5 mL]	Ar	25 °C	48 h	87 mg	92:8	Solvent Type
10	SMEAH [70% in MePh, 15 equiv]	Et ₂ O [5 mL]	Ar	25 °C	48 h	120 mg	89:11	
11	SMEAH [70% in MePh, 15 equiv]	dioxane [5 mL]	Ar	25 °C	48 h	50 mg	93:7	
12	SMEAH [70% in MePh, 15 equiv]	DME [5 mL]	Ar	25 °C	48 h	61 mg	92:8	
13	SMEAH [70% in MePh, 15 equiv]	THF [5 mL]	Dry air	25 °C	3 h	75 mg	93:7	Atm.
14	SMEAH [70% in MePh, 15 equiv]	THF [5 mL]	O ₂	25 °C	3 h	182 mg	94:6	

Footnotes: Experiments were performed at the 1.3 mmol scale; SMEAH = sodium bis(2-methoxyethoxy)aluminum hydride, DME = dimethoxyethane; ^abased on the isolated yields, ^b measured by ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analyses of the isolated products (**Fig. S1**).




Figure S1. ^1H NMR (400 MHz, $\text{DMSO}-d_6$, 35 $^\circ\text{C}$) analysis of the isolated product mixtures of **Entries 6–8** and **14** (in detail).

HPLC conditions: an YMC-Triart C_{18} column (3 μm , 150 $\times$ 2.0 mm), MeCN –50mM HCOONH_4 (pH = 9.30), 40:60, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 230 nm).




Figure S2. RP-HPLC analysis of the **4a** prepared according to the **Entry 6** (Tab. S2).

2. Substrate Scope

2.1 The reduction of **1a**





Figure S3. Visual progress and TLC analysis of the crude reaction mixture of **1a** after 3 h (SiO₂, CH₂Cl₂–MeOH, 9:1).

HPLC conditions: an YMC-Triart C₁₈ column (3 μ m, 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 40:60, 0.2 mL/min, 40 °C (λ = 230 nm).




Figure S4. RP-HPLC analysis of the precipitate from the reduction of **1a** showing **3a/4a** = 94:6 (external standard calibration method).





Figure S5. ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analysis of the precipitate from the reduction of **1a** showing **3a/4a** = 94:6.

2.2 The reduction of **1ad**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 40:60, 0.2 mL/min, 40 °C (λ = 230 nm).




Figure S6. RP-HPLC analysis of the precipitate from the reduction of **1ad** showing **3a/4a** = 63:37 (external standard calibration method).





Figure S7. ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analysis of the precipitate from the reduction of **1ad** showing **3a/4a** = 62:38.

2.3 The reduction of **1b**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 20:80, 0.2 mL/min, 40 °C (λ = 210 nm).




Figure S8. HPLC analysis of the authentic sample of **3b**.




Figure S9. HPLC analysis of the authentic sample of **4b**. Note: the first peak corresponds to oxalic acid.




Figure S10. HPLC analysis of the precipitate from the reduction of **1b** under O_2 atmosphere showing **3b/4b** = 95:5 (external standard calibration method). Note: the first peak corresponds to oxalic acid.





Figure S11. HPLC analysis of the precipitate from the reduction of **1b** under Ar atmosphere showing **3b/4b** = 81:19 (external standard calibration method). Note: the first peak corresponds to oxalic acid.

2.4 The reduction of **1ba**



HPLC conditions: an YMC-Triart C₁₈ column (3 μ m, 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 20:80, 0.2 mL/min, 40 $^{\circ}$ C (λ = 210 nm).





Figure S12. HPLC analysis of the precipitate from the reduction of **1ba** showing **3b**. Note: the first peak corresponds to oxalic acid.

2.5 The reduction of **1bb**



HPLC conditions: an YMC-Triart C_{18} column ($3\ \mu\text{m}$, $150 \times 2.0\ \text{mm}$), MeCN – 50mM HCOONH_4 ($\text{pH} = 9.30$), $20:80$, $0.2\ \text{mL/min}$, $40\ ^\circ\text{C}$ ($\lambda = 210\ \text{nm}$).




Figure S13. HPLC analysis of the precipitate from the reduction of **1bb** showing **3b/4ba** = 29:71 (external standard calibration method). Note: the first peak corresponds to oxalic acid.





Figure S14. ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analysis of the precipitate from the reduction of **1bb** showing **3b**/**4ba** = 30:70.

2.6 The reduction of **1bc**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 20:80, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S15. HPLC analysis of the precipitate from the reduction of **1bc** showing **3b**. Note: the first peak corresponds to oxalic acid.

2.7 The reduction of **1c**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 30:70, 0.2 mL/min, 40 $^{\circ}\text{C}$ (λ = 210 nm).




Figure S16. HPLC analysis of the precipitate from the reduction of **1c** showing **3c/4c** = 95:5 (external standard calibration method). Note: the first peak corresponds to oxalic acid.





Figure S17. ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analysis of the precipitate from the reduction of **1c** showing **3c/4c** = 95:5.

2.8 The reduction of **1ca**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 30:70, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S18. HPLC analysis of the precipitate from the reduction of **1ca** showing **3c**. Note: the first peak corresponds to oxalic acid.

2.9 The reduction of **1cb**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 30:70, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S19. HPLC analysis of the precipitate from the reduction of **1cb** showing **3ca**. Note: the first peak corresponds to oxalic acid.

2.10 The reduction of **1cc**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 40:60, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S20. HPLC analysis of the precipitate from the reduction of **1cc** showing **3cb**. Note: the first peak corresponds to oxalic acid.

2.11 The reduction of **1d**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 40:60, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S21. HPLC analysis of the precipitate from the reduction of **1d** showing **3d**. Note: the first peak corresponds to oxalic acid.

2.12 The reduction of **1da**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 40:60, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S22. HPLC analysis of the precipitate from the reduction of **1da** showing **3d**. Note: the first peak corresponds to oxalic acid.

2.13 The reduction of **1e**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 50:50, 0.2 mL/min, 40 °C (λ = 210 nm).




Figure S23. HPLC analysis of the precipitate from the reduction of **1e** showing **3e**.





Figure S24. ^1H NMR (400 MHz, DMSO-d_6 , 35 °C) analysis of the precipitate from the reduction of **1e** showing **3e/4e** = 97:3.

2.14 The reduction of **1f**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 50:50, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 210 nm).




Figure S25. HPLC analysis of the precipitate from the reduction of **1f** showing **3f/4f** = 94:6 (external standard calibration method).





Figure S26. ^1H NMR (400 MHz, $\text{DMSO}-d_6$, 35 °C) analysis of the precipitate from the reduction of **1f** showing **3f/4f** = 93:7.

2.15 The reduction of **1g**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 30:70, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 230 nm).





Figure S27. HPLC analysis of the precipitate from the reduction of **1g** showing **3g/4g** = 95:5 (external standard calibration method).

2.16 The reduction of **1h**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 20:80, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 230 nm).





Figure S28. HPLC analysis of the precipitate from the reduction of **1h** showing **3h/4h** = 97:3 (external standard calibration method).

2.17 The reduction of **2a**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 40:60, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 230 nm).




Figure S29. RP-HPLC analysis of the precipitate from the reduction of **1a** showing **3a/4a** = 89:11 (external standard calibration method).





Figure S30. ^1H NMR (400 MHz, DMSO-d_6 , 35 °C) analysis of the precipitate from the reduction of **1a** showing **3a/4a** = 89:11.

2.18 The reduction of **2b**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 20:80, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S31. HPLC analysis of the precipitate from the reduction of **2b** showing **3b**. Note: the first peak corresponds to oxalic acid.

2.19 The reduction of **2ba**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 20:80, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S32. HPLC analysis of the precipitate from the reduction of **2ba** showing **3b**. Note: the first peak corresponds to oxalic acid.

2.20 The reduction of **2c**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 30:70, 0.2 mL/min, 40 °C (λ = 210 nm).




Figure S33. RP-HPLC analysis of the precipitate from the reduction of **2c** showing **3c/4c** = 94:6 (external standard calibration method). Note: the first peak corresponds to oxalic acid.





Figure S34. ^1H NMR (400 MHz, $\text{DMSO-}d_6$, 35 °C) analysis of the precipitate from the reduction of **1c** showing **3c**/**4c** = 94:6.

2.21 The reduction of **2d**



HPLC conditions: an YMC-Triart C_{18} column ($3\ \mu\text{m}$, $150 \times 2.0\ \text{mm}$), MeCN–50mM HCOONH_4 (pH = 9.30), 40:60, 0.2 mL/min, $40\ ^\circ\text{C}$ ($\lambda = 210\ \text{nm}$).




Figure S35. RP-HPLC analysis of the precipitate from the reduction of **2d** showing **3d/4d** = 92:8 (external standard calibration method). Note: the first peak corresponds to oxalic acid.




Figure S36. ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analysis of the precipitate from the reduction of **2d** showing **3d/4d** = 92:8.





Figure S37. RP-HPLC analysis of the precipitate from the reduction of **2d** with added NaCN (10 equiv) showing **3d/4d** = 99:1 (external standard calibration method). Note: the first peak corresponds to oxalic acid.

2.22 The reduction of **2da**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 40:60, 0.2 mL/min, 40 °C (λ = 210 nm).





Figure S38. RP-HPLC analysis of the precipitate from the reduction of **2da** showing **3d**. Note: the first peak corresponds to oxalic acid.

2.23 The reduction of **2e**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 50:50, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 210 nm).




Figure S39. RP-HPLC analysis of the precipitate from the reduction of **2e** showing **3e/4e** = 93:7 (external standard calibration method). Note: the first peak corresponds to oxalic acid.




Figure S40. ¹H NMR (400 MHz, DMSO-*d*₆, 35 °C) analysis of the precipitate from the reduction of **1e** showing **3e/4e** = 91:9.





Figure S41. ¹⁹F NMR (376 MHz, DMSO-*d*₆, 35 °C) analysis of the precipitate from the reduction of **1e** showing **3e/4e** = 89:11.

2.24 The reduction of **2f**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 50:50, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 210 nm).




Figure S42. HPLC analysis of the precipitate from the reduction of **2f** showing **3f/4f** = 97:3 (external standard calibration method). Note: the first peak corresponds to oxalic acid.





Figure S43. ^1H NMR (400 MHz, $\text{DMSO}-d_6$, 35 °C) analysis of the precipitate from the reduction of **1f** showing $\mathbf{3f/4f} = 96:4$.

2.25 The reduction of **2g**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 30:70, 0.2 mL/min, 40 °C (λ = 230 nm).





Figure S44. HPLC analysis of the precipitate from the reduction of **2g** showing **3g**.

2.26 The reduction of **2h**



HPLC conditions: an YMC-Triart C₁₈ column (3 μm , 150 $\times$ 2.0 mm), MeCN–50mM HCOONH₄ (pH = 9.30), 20:80, 0.2 mL/min, 40 $^\circ\text{C}$ (λ = 230 nm).






Figure S45. HPLC analysis of the precipitate from the reduction of **2h** showing **3h/4h** = 96:4 (external standard calibration method).

3. Determination of the Enantiomeric Purity of 8a, 8b, and 5a




HPLC conditions: a Hypersil silica column (3 μ m, 100 $\times$ 4.6 mm used as a precolumn, which was connected via the standard blue PEEK capillary tubing (L 300 mm, ID 0.01", OD 1/16") to a Daicel Chiralpak IA column (5 μ m, 250 $\times$ 4.6 mm), *i*-PrOH–*n*-heptane, 10:90, 0.5 mL/min, 25 $^{\circ}$ C (λ = 230 nm).




Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		36.360	246387.406	16595349.000	49.9440
2		49.382	143238.063	16632589.000	50.0560
Total			389625.469	33227938.000	100.0000

Figure S46. Chiral HPLC chromatogram of **8a** (0% ee).




Stereochemical assignment: Absolute configuration of (R)-5 was established by comparison of the sign of specific rotation and the relative elution order of the resolved peaks with literature data.¹

HPLC conditions: a Hypersil silica column (3 μm , 100 $\times$ 4.6 mm used as a precolumn, which was connected via the standard blue PEEK capillary tubing (L 300 mm, ID 0.01", OD 1/16") to a Daicel Chiralpak IB column (5 μm , 250 $\times$ 4.6 mm), *i*-PrOH–*n*-heptane, 5:95, 0.5 mL/min, 25 °C (λ = 230 nm).




Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		28.978	262292.688	10607185.000	49.8585
2		34.872	231386.391	10667406.000	50.1415
Total			493679.078	21274591.000	100.0000

Figure S47. Chiral HPLC chromatogram of *rac*-5a (0% ee).




Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		28.503	30436.004	1223150.625	47.0368
2		34.070	27920.609	1377261.625	52.9632
Total			58356.613	2600412.250	100.0000

Figure S48. Chiral HPLC chromatogram of (*R*)-**5a** (6% ee).




Stereochemical assignment: Absolute configuration of **(S)-8b** was established by chemical correlation with **(S)-1ba**.

HPLC conditions: a Hypersil silica column (3 μm , 100 $\times$ 4.6 mm used as a precolumn, which was connected via the standard blue PEEK capillary tubing (L 300 mm, ID 0.01", OD 1/16") to a Daicel Chiralpak IA column (5 μm , 250 $\times$ 4.6 mm), *i*-PrOH–*n*-heptane, 10:90, 0.5 mL/min, 25 $^{\circ}\text{C}$ (λ = 230 nm).



Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		58.085	25900.541	2261213.750	49.9107
2		60.857	23239.223	2269307.250	50.0893
Total			49139.764	4530521.000	100.0000


Figure S49. Chiral HPLC chromatogram of *rac*-**8b** (0% ee).



Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		57.507	130975.086	13684664.000	100.0000
Total			130975.086	13684664.000	100.0000

Figure S50. Chiral HPLC chromatogram of (*S*)-**8b** (> 99% ee).

4. Identification of the Reaction Intermediates



The reduction of **1d** (275 mg, 1.3 mmol) was performed according to **GP**. The precipitated salt was filtered off and afforded 101 mg of **3d**·H₂C₂O₄ as a white hygroscopic powder (26% yield). The crude filtrate was treated according to **GP** and provided 130 mg of the yellowish waxy residue, which contained **5c** as a major component (HPLC purity > 90%). Then the residue (120 mg) was subjected to column chromatography (120 × 15 mm), 10 g of SiO₂, *n*-heptane–EtOAc (9:1), and fractions of 10 mL each were collected.

The combined fractions **2–3** gave after evaporation 6 mg of the residue, which was subjected to NMR and GC-MS analysis. Therein, compounds **2d**, **6**, and **7** were successfully identified. The combined fractions **5–7** provided 81 mg of the pure **5c**.

HPLC conditions: an YMC-Triart C₁₈ column (3 μm, 150 × 2.0 mm), MeCN–H₂O, 50:50 → 90:10, 0.2 mL/min, 40 °C (λ = 210 nm).




Figure S51. HPLC profile of the crude filtrate (210 nm).




Figure S52. ^1H NMR (CDCl_3 , 400 MHz) profile of the crude filtrate.




Figure S53. ^1H NMR (CDCl_3 , 400 MHz) profile of the crude filtrate (in detail).




Figure S54. ^{13}C NMR (CDCl₃, 100 MHz) profile of the crude filtrate.




Figure S55. ^{13}C NMR (CDCl₃, 100 MHz) profile of the crude filtrate (in detail).

GC conditions: a DB-5MS column (0.25 μ m, 30 m $\times$ 0.25 mm), He (constant flow 1 mL/min), temperature program (50 $^{\circ}$ C | hold 2 min; 10 $^{\circ}$ C/min rate to 300 $^{\circ}$ C | hold 15 min).




Figure S56. GC profile of the fractions 2–3.




Figure S57. MS spectrum of the peak 16.23 min corresponding to the compound 6.




Figure S58. MS spectrum of the peak 17.04 min corresponding to the compound **2d**.




Figure S59. MS spectrum of the peak 31.65 min corresponding to the compound **7**.




Figure S60. ^1H NMR (CDCl₃, 400 MHz) profile of the fractions **2–3** in comparison with the authentic spectra of **6**, **2d**, and **7**.




Figure S61. ^1H NMR (CDCl₃, 400 MHz) profile of the fractions **2–3** in comparison with the authentic spectra of **6**, **2d**, and **7** (in detail).




Figure S62. ^{13}C NMR (CDCl₃, 100 MHz) profile of the fractions 2–3 in comparison with the authentic spectra of **6**, **2d**, and **7**.




Figure S63. ^{13}C NMR (CDCl₃, 100 MHz) profile of the fractions 2–3 in comparison with the authentic spectra of **6**, **2d**, and **7** (in detail).

GC conditions: a DB-5MS column (0.25 μm , 30 m $\times$ 0.25 mm), He (constant flow 1 mL/min), temperature program (50 $^{\circ}\text{C}$ | hold 2 min; 10 $^{\circ}\text{C}/\text{min}$ rate to 300 $^{\circ}\text{C}$ | hold 15 min).




Figure S64. GC profile of the fractions **5–7** corresponding to the compound **5c**.




Figure S65. GC spectrum showing slow degradation of the sample containing **5c** on the air.




Figure S66. MS spectrum of the peak 16.27 min corresponding to the compound **5c**.




Figure S67. MS spectrum of the peak 25.66 min corresponding to the benzopinacol artifact.




Figure S68. ^1H NMR (CDCl₃, 400 MHz) profile of the fractions **5–7** corresponding to the compound **5c**.




Figure S69. ^1H NMR (CDCl₃, 400 MHz) profile of the fractions **5–7** corresponding to the compound **5c** (in detail).




Figure S70. ¹³C NMR (CDCl₃, 100 MHz) profile of the fractions **5–7** corresponding to the compound **5c**.




Figure S71. ¹³C NMR (CDCl₃, 100 MHz) profile of the fractions **5–7** corresponding to the compound **5c** (in detail).

5. References

- (1) J. Xiao, Z. Z. Wong, Y. P. Lu and T. P. Loh, *Adv. Synth. Catal.* 2010, **352**, 1107.

6. HRMS and NMR Data




Figure S72. HRMS (ESI-Q-TOF) spectrum of **1aa** $[M+H]^+$.




Figure S73. HRMS (ESI-Orbitrap) spectrum of **1ab** $[M+H]^+$.




Figure S74. HRMS (ESI-Orbitrap) spectrum of **1ac** $[M+H]^+$.




Figure S75. HRMS (ESI-Orbitrap) spectrum of **1ad** $[M-H]^-$.




Figure S76. HRMS (ESI-Orbitrap) spectrum of **1b** $[M+H]^+$.




Figure S77. HRMS (ESI-Orbitrap) spectrum of **1ba** $[M-H]^-$.




Figure S78. HRMS (ESI-Orbitrap) spectrum of **1bb** $[M+H]^+$.




Figure S79. HRMS (ESI-Orbitrap) spectrum of **1bc** $[M-H]^-$.




Figure S80. HRMS (ESI-Orbitrap) spectrum of **1bd** $[M+H]^+$.




Figure S81. HRMS (ESI-Orbitrap) spectrum of **1c** $[M+H]^+$.




Figure S82. HRMS (ESI-Orbitrap) spectrum of **1ca** $[M-H]^-$.




Figure S83. HRMS (ESI-Orbitrap) spectrum of **1cb** $[M-H]^-$.




Figure S84. HRMS (ESI-Orbitrap) spectrum of **1cc** $[M+H]^+$.




Figure S85. HRMS (ESI-Orbitrap) spectrum of **1d** $[M+H]^+$.




Figure S86. HRMS (ESI-Orbitrap) spectrum of **1da** $[M-H]^-$.




Figure S87. HRMS (ESI-Orbitrap) spectrum of **1e** $[M+H]^+$.




Figure S88. HRMS (ESI-Orbitrap) spectrum of **1f** $[M+H]^+$.




Figure S89. HRMS (ESI-Orbitrap) spectrum of **1g** $[M+H]^+$.




Figure S90. HRMS (ESI-Orbitrap) spectrum of **1h** $[M+H]^+$.




Figure S91. HRMS (ESI-Orbitrap) spectrum of **2a** $[M-H]^-$.




Figure S92. HRMS (ESI-Orbitrap) spectrum of **2ba** $[M+H]^+$.




Figure S93. HRMS (ESI-Orbitrap) spectrum of **2c** $[M+H]^+$.




Figure S94. HRMS (ESI-Orbitrap) spectrum of **2da** $[M-H]^-$.




Figure S95. HRMS (ESI-Orbitrap) spectrum of **2e** $[M+H]^+$.




Figure S96. HRMS (ESI-Orbitrap) spectrum of **2f** $[M+H]^+$.




Figure S97. HRMS (ESI-Orbitrap) spectrum of **2g** $[M+H]^+$.




Figure S98. HRMS (ESI-Orbitrap) spectrum of **2h** $[M+H]^+$.




Figure S99. HRMS (ESI-Q-TOF) spectrum of **3a** $[M+H]^+$.




Figure S100. HRMS (ESI-Obitrap) spectrum of **3b** $[M+H]^+$.




Figure S101. HRMS (ESI-Q-TOF) spectrum of **3c** $[M+H]^+$.




Figure S102. HRMS (ESI-Q-TOF) spectrum of **3ca** $[M+H]^+$.




Figure S103. HRMS (ESI-Q-TOF) spectrum of **3cb** $[M+H]^+$.




Figure S104. HRMS (ESI-Q-TOF) spectrum of **3d** $[M+H]^+$.




Figure S105. HRMS (ESI-Q-TOF) spectrum of **3e** $[M+H]^+$.




Figure S106. HRMS (ESI-Q-TOF) spectrum of **3f** $[M+H]^+$.




Figure S107. HRMS (ESI-Q-TOF) spectrum of **3g** $[M+H]^+$.

2020_01_16_pos_Identifikace_Bobal_1_3 #118 RT: 1.70 AV: 1 NL: 3.34E8
T: FTMS + p ESI Full ms [50.00-1000.00]




Figure S108. HRMS (ESI-Orbitrap) spectrum of **3h** $[M+H]^+$.




Figure S109. HRMS (ESI-Q-TOF) spectrum of **4a** $[M+H]^+$.




Figure S110. HRMS (ESI-Q-TOF) spectrum of **4aa** $[M+H]^+$.




Figure S111. HRMS (ESI-Q-TOF) spectrum of **4ba** $[M+H]^+$.




Figure S112. HRMS (ESI-Orbitrap) spectrum of **4bb** $[M+H]^+$.




Figure S113. HRMS (ESI-Q-TOF) spectrum of **4f** $[M+H]^+$.

2020_01_16_pos_Identifikace_Bobal_1_17 #830 RT: 12.09 AV: 1 NL: 4.49E5
T: FTMS + p ESI Full ms [50.00-1000.00]




Figure S114. HRMS (ESI-Orbitrap) spectrum of **5a** $[M+H]^+$.

2020_01_16_pos_Identifikace_Bobal_1_21 #1128 RT: 16.43 AV: 1 NL: 4.07E5
T: FTMS + p ESI Full ms [50.00-1000.00]




Figure S115. HRMS (ESI-Orbitrap) spectrum of **5c** $[M+H]^+$.

2020_01_16_pos_Identifikace_Bobal_1_19 #1196 RT: 17.41 AV: 1 NL: 2.22E7
T: FTMS + p ESI Full ms [50.00-1000.00]




Figure S116. HRMS (ESI-Orbitrap) spectrum of **5d** $[M-H_2O+H]^+$.

2020_01_16_pos_Identifikace_Bobal_1_20 #995 RT: 14.48 AV: 1 NL: 1.34E4
T: FTMS - p ESI Full ms [50.00-1000.00]




Figure S117. HRMS (ESI-Orbitrap) spectrum of **5e** $[M+H]^+$.

2020_01_16_neg_Identifikace_Bobal_1_26 #1260 RT: 19.28 AV: 1 NL: 6.13E7
T: FTMS - p ESI Full ms [50.00-1000.00]




Figure S118. HRMS (ESI-Orbitrap) spectrum of **8a** $[M-H]^-$.

2020_01_16_neg_Identifikace_Bobal_1_26 #1182 RT: 17.89 AV: 1 NL: 1.43E8
T: FTMS - p ESI Full ms [65.00-1000.00]




Figure S119. HRMS (ESI-Orbitrap) spectrum of **8b** $[M-H]^-$.

2020_01_16_pos_Identifikace_Bobal_1_24 #904 RT: 13.17 AV: 1 NL: 9.15E8
T: FTMS + p ESI Full ms [50.00-1000.00]




Figure S120. HRMS (ESI-Orbitrap) spectrum of **9** $[M+H]^+$.

2020_01_16_neg_Identifikace_Bobal_1_25 #1265 RT: 19.22 AV: 1 NL: 9.03E7
T: FTMS - p ESI Full ms [65.00-1000.00]




Figure S121. HRMS (ESI-Orbitrap) spectrum of **10** $[M-H]^-$.




Figure S122. ^1H NMR (400 MHz, DMSO- d_6) spectrum of **1aa**.




Figure S123. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **1aa**.




Figure S124. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **1ab**.




Figure S125. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **1ab**.




Figure S126. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **1ac**.




Figure S127. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **1ac**.




Figure S128. ¹H NMR (400 MHz, CDCl₃) spectrum of **1ad**.




Figure S129. ^{13}C NMR APT (100 MHz, CDCl_3) spectrum of **1ad**.




Figure S130. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1b**.




Figure S131. ¹³C NMR (100 MHz, DMSO-*d*₆) spectrum of **1b**.




Figure S132. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1ba**.




Figure S133. ¹³C NMR (100 MHz, DMSO-*d*₆) spectrum of **1ba**.




Figure S134. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1bb**.




Figure S135. ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) spectrum of **1bb**.




Figure S136. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **1bc**.




Figure S137. ^{13}C NMR APT (100 MHz, DMSO- d_6) spectrum of **1bc**.




Figure S138. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1bd**.




Figure S139. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **1bd**.




Figure S140. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1c**.




Figure S141. ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) spectrum of **1c**.




Figure S142. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1ca**.




Figure S143. ^{13}C NMR APT (100 MHz, $\text{DMSO}-d_6$) spectrum of **1ca**.





Figure S144. ^{19}F NMR (376 MHz, $\text{DMSO-}d_6$) spectrum of **1ca**.




Figure S145. ^1H NMR (400 MHz, CDCl_3) spectrum of **1cb**.




Figure S146. ¹³C NMR APT (100 MHz, CDCl₃) spectrum of **1cb**.





Figure S147. ^{19}F NMR (376 MHz, CDCl_3) spectrum of **1cb**.




Figure S148. ^1H NMR (400 MHz, CDCl_3) spectrum of **1cc**.




Figure S149. ^{13}C APT NMR (100 MHz, CDCl_3) spectrum of **1cc**.




Figure S150. ^1H NMR (400 MHz, CDCl_3) spectrum of **1d**.




Figure S151. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1d**.




Figure S152. ¹³C NMR (100 MHz, DMSO-*d*₆) spectrum of **1d**.




Figure S153. ^1H NMR (400 MHz, CDCl_3) spectrum of **1da**.




Figure S154. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1da**.




Figure S155. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **1da**.




Figure S156. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) spectrum of **1e**.




Figure S157. ¹³C NMR (100 MHz, DMSO-*d*₆) spectrum of **1e**.





Figure S158. ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) spectrum of **1e**.




Figure S159. ^1H NMR (400 MHz, DMSO-d_6) spectrum of **1f**.




Figure S160. ¹³C NMR (100 MHz, DMSO-*d*₆) spectrum of **1f**.




Figure S161. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **1g**.




Figure S162. ^{13}C NMR APT (100 MHz, DMSO- d_6) spectrum of **1g**.




Figure S163. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **1h**.




Figure S164. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **1h**.




Figure S165. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **2a**.




Figure S166. ^{13}C NMR APT (100 MHz, $\text{DMSO-}d_6$) spectrum of **2a**.




Figure S167. ^1H NMR (400 MHz, CDCl_3) spectrum of **2ba**.




Figure S168. ^{13}C APT NMR (100 MHz, CDCl_3) spectrum of **2ba**.




Figure S169. ^1H NMR (400 MHz, CDCl_3) spectrum of **2c**.




Figure S170. ^{13}C NMR APT (100 MHz, CDCl_3) spectrum of **2c**.




Figure S171. ¹H NMR (400 MHz, CDCl₃) spectrum of **2da**.




Figure S172. ¹³C NMR APT (100 MHz, CDCl₃) spectrum of **2da**.




Figure S173. ¹H NMR (400 MHz, CDCl₃) spectrum of **2e**.




Figure S174. ^{13}C APT NMR (100 MHz, CDCl_3) spectrum of **2e**.





Figure S175. ^{19}F NMR (376 MHz, CDCl_3) spectrum of **2e**.




Figure S176. ^1H NMR (400 MHz, CDCl_3) spectrum of **2f**.




Figure S177. ^{13}C APT NMR (100 MHz, CDCl_3) spectrum of **2f**.




Figure S178. ^1H NMR (400 MHz, CDCl_3) spectrum of **2g**.




Figure S179. ¹³C APT NMR (100 MHz, CDCl₃) spectrum of 2g.




Figure S180. ¹H NMR (400 MHz, CDCl₃) spectrum of **2h**.




Figure S181. ^{13}C APT NMR (100 MHz, CDCl_3) spectrum of **2h**.




Figure S182. ¹H NMR (400 MHz, DMSO-d₆) spectrum of **3a** · H₂C₂O₄.




Figure S183. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3a** · H₂C₂O₄.




Figure S184. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **3b** · H₂C₂O₄.




Figure S185. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3b** • H₂C₂O₄.




Figure S186. ¹H NMR (400 MHz, DMSO-d₆) spectrum of **3c** · H₂C₂O₄.




Figure S187. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3c** • H₂C₂O₄.




Figure S188. ¹H NMR (400 MHz, DMSO-d₆) spectrum of **3ca** • H₂C₂O₄.




Figure S189. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3ca** • H₂C₂O₄.




Figure S190. ¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum of **3ca** · H₂C₂O₄.




Figure S191. ¹H NMR (400 MHz, DMSO-d₆) spectrum of **3cb** • H₂C₂O₄.




Figure S192. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3cb** • H₂C₂O₄.




Figure S193. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **3d**·H₂C₂O₄.




Figure S194. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3d**·H₂C₂O₄.




Figure S195. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **3e** · H₂C₂O₄.




Figure S196. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3e** • H₂C₂O₄.





Figure S197. ¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum of **3e** • H₂C₂O₄.




Figure S198. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **3f** · H₂C₂O₄.




Figure S199. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3f**·H₂C₂O₄.




Figure S200. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **3g** · H₂C₂O₄.




Figure S201. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3g** · H₂C₂O₄.




Figure S202. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **3h** · H₂C₂O₄.




Figure S203. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **3h** · H₂C₂O₄.




Figure S204. ¹H NMR (400 MHz, DMSO-d₆) spectrum of **4a** • H₂C₂O₄.




Figure S205. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **4a** • H₂C₂O₄.




Figure S206. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **4aa** • H₂C₂O₄.




Figure S207. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **4aa** • H₂C₂O₄.




Figure S208. Comparison of ¹H NMR (400 MHz, DMSO-*d*₆) spectra of the pure **3b** • H₂C₂O₄ and the mixture of **3b** • H₂C₂O₄ and **4ba** • H₂C₂O₄ (29:71).
S-164




Figure S209. Comparison of ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) spectra of the pure **3b** $\cdot$ $\text{H}_2\text{C}_2\text{O}_4$ and the mixture of **3b** $\cdot$ $\text{H}_2\text{C}_2\text{O}_4$ and **4ba** $\cdot$ $\text{H}_2\text{C}_2\text{O}_4$ (29:71).
S-165




Figure S210. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **4bb** · H₂C₂O₄.




Figure S211. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **4bb** • H₂C₂O₄.




Figure S212. ¹H NMR (400 MHz, DMSO-*d*₆) spectrum of **4f** · H₂C₂O₄.




Figure S213. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **4f**·H₂C₂O₄.




Figure S214. ¹H NMR (400 MHz, CDCl₃) spectrum of **5a**.




Figure S215. ¹³C NMR APT (100 MHz, CDCl₃) spectrum of **5a**.




Figure S216. ^1H NMR (400 MHz, CDCl_3) spectrum of **5b**.




Figure S217. ¹³C NMR APT (100 MHz, CDCl₃) spectrum of **5b**.




Figure S218. ^1H NMR (400 MHz, CDCl_3) spectrum of **5c**.




Figure S219. ^{13}C NMR APT (100 MHz, CDCl_3) spectrum of **5c**.




Figure S220. ^1H NMR (400 MHz, CDCl_3) spectrum of **5d**.




Figure S221. ¹³C NMR APT (100 MHz, CDCl₃) spectrum of **5d**.





Figure S222. ^{19}F NMR (376 MHz, CDCl_3) spectrum of **5d**.




Figure S223. ¹H NMR (400 MHz, CDCl₃) spectrum of **5e**.




Figure S224. ¹³C NMR APT (100 MHz, CDCl₃) spectrum of **5e**.




Figure S225. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) spectrum of **8a**.




Figure S226. ¹³C NMR APT (100 MHz, DMSO-*d*₆) spectrum of **8a**.




Figure S227. ¹H NMR (400 MHz, CDCl₃) spectrum of **8b**.




Figure S228. ^{13}C NMR APT (100 MHz, CDCl_3) spectrum of **8b**.




Figure S229. ^1H NMR (400 MHz, CDCl_3) spectrum of **9**.




Figure S230. ^{13}C NMR APT (100 MHz, CDCl_3) spectrum of **9**.




Figure S231. ¹⁹F NMR (376 MHz, CDCl₃) spectrum of **9**.




Figure S232. ^1H NMR (400 MHz, CDCl_3) spectrum of **10**.





Figure S233. ¹³C NMR APT (100 MHz, CDCl₃) spectrum of **10**.




Figure S234. ¹⁹F NMR (376 MHz, CDCl₃) spectrum of **10**.